Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients
- 20 December 1996
- journal article
- Published by Elsevier BV in Cancer Letters
- Vol. 110 (1-2), 137-144
- https://doi.org/10.1016/s0304-3835(96)04473-4
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3European Journal of Cancer and Clinical Oncology, 1991
- Use of mucin like cancer associated antigen (MCA) in the management of breast cancerBritish Journal of Cancer, 1991
- Clinical Applications of Serum Tumor MarkersAnnals of Internal Medicine, 1991
- The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 casesBritish Journal of Cancer, 1991
- CA-15.3, TPA and MCA as markers for breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic diseaseCancer, 1989
- Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancerEuropean Journal of Cancer and Clinical Oncology, 1989
- Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast TumorsHybridoma, 1984
- CEA (carcinoembryonic antigen): Its role as a marker in the management of cancerZeitschrift für Krebsforschung und Klinische Onkologie, 1981
- DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUESThe Journal of Experimental Medicine, 1965